Jordan Johnson, Founder and Principal at Bridge Oncology and Legal Data Expert, shared a post on LinkedIn:
“AI in Healthcare Just Crossed a Line and Oncology Is at the Center
The December executive order on AI didn’t relax responsibility. It concentrated it.
By blocking fragmented state-level AI regulation and shifting toward a federal-first AI governance model, the message from Washington is clear:
AI in healthcare is no longer experimental. It is regulated infrastructure.
For hospitals and health systems especially in oncology this is not a legal footnote. It is an operational inflection point.
CIOs, CMOs, and compliance leaders are now asking hard questions:
- Where does AI inform vs decide?
- Who owns risk when models drift or bias appears?
- Are vendors accountable or insulated?
Can AI deployments withstand CMS, OIG, DOJ, and payer scrutiny?
Is documentation defensible after the lookback?
At Bridge Oncology, we’re engaging the HHS AI Request for Information (RFI) because this moment demands real-world oncology expertise, not abstract policy theory.
Together with tensorblack Black, we are helping define AI for oncology across the full lifecycle:
- Discovery → what the tool actually does
- Vetting → FDA, data provenance, bias, explainability
- Compliance → HIPAA, CMS, payer, supervision, liability
- Adoption → workflows, reimbursement, audit readiness
This is context engineering, not tool deployment.
AI governance cannot live in IT committees alone.
It must live where risk actually exists:
- Clinical pathways
- Documentation and coding
- Prior authorization and utilization
- Revenue cycle and audits
- The systems that will lead are those that:
Anchor AI governance to federal frameworks (not geographic noise)
Demand enforceable accountability from vendors
Treat AI as clinical, operational, financial, and legal infrastructure
Build for enforcement reality not innovation headlines
The federal runway is being built.
We are already operating on it.
AI in oncology is no longer about experimentation.
It’s about execution and defensibility.”
More posts featuring Jordan Johnson on OncoDaily.